Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B‐mediated drug–drug interactions using population pharmacokinetic …

S Barnett, K Ogungbenro, K Ménochet… - Clinical …, 2018 - Wiley Online Library
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin …
被引用次数：64 相关文章

Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modelling …

S Barnett, K Ogungbenro… - Clinical …, 2018 - research.manchester.ac.uk
This study evaluates coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B-mediated drug-drug interactions (DDIs) relative to clinical probe rosuvastatin using …
[HTML] nih.gov

[HTML][HTML] Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population …

S Barnett, K Ogungbenro, K Ménochet… - Clinical …, 2018 - ncbi.nlm.nih.gov
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin …

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic …

S Barnett, K Ogungbenro, K Ménochet… - Clinical …, 2018 - europepmc.org
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin …

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic …

S Barnett, K Ogungbenro, K Ménochet… - Clinical …, 2018 - eprints.ncl.ac.uk
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin …

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic …

S Barnett, K Ogungbenro, A Galetin… - Clinical …, 2018 - search.ebscohost.com
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin …

[引用][C] Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic …

S Barnett, K Ogungbenro, K Ménochet, H Shen… - Clinical Pharmacology …, 2018 - cir.nii.ac.jp
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated
Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation | CiNii …

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic …

S Barnett, K Ogungbenro… - Clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B-mediated drug-drug interactions (DDIs) relative to clinical probe rosuvastatin using …

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic …

S Barnett, K Ogungbenro, K Ménochet… - Clinical …, 2018 - europepmc.org
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B-mediated drug-drug interactions (DDIs) relative to clinical probe rosuvastatin using …